Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401
Phase 1Completed 0 views this week 0 watching💤 Quiet
Interest: 19/100
19
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Metastatic Melanoma
Conditions
Metastatic Melanoma
Trial Timeline
Jan 28, 2019 → Mar 4, 2022
NCT ID
NCT03817125About Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401
Placebo for antibiotic + Vancomycin pretreatment + Nivolumab + Matching Placebo for SER-401 + SER-401 is a phase 1 stage product being developed by Seres Therapeutics for Metastatic Melanoma. The current trial status is completed. This product is registered under clinical trial identifier NCT03817125. Target conditions include Metastatic Melanoma.
What happened to similar drugs?
20 of 20 similar drugs in Metastatic Melanoma were approved
Approved (20) Terminated (8) Active (0)
Hype Score Breakdown
Clinical
6
Activity
8
Company
5
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03817125 | Phase 1 | Completed |
Competing Products
20 competing products in Metastatic Melanoma